CA3026412A1 - Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells - Google Patents

Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells Download PDF

Info

Publication number
CA3026412A1
CA3026412A1 CA3026412A CA3026412A CA3026412A1 CA 3026412 A1 CA3026412 A1 CA 3026412A1 CA 3026412 A CA3026412 A CA 3026412A CA 3026412 A CA3026412 A CA 3026412A CA 3026412 A1 CA3026412 A1 CA 3026412A1
Authority
CA
Canada
Prior art keywords
sbt
dha
pufa
oil
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3026412A
Other languages
English (en)
French (fr)
Inventor
James E. Egan
Iwao Ojima
Mansoor M. Amiji
Galina Ivanovna BOTCHKINA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Targagenix Inc
Northeastern University Boston
Research Foundation of the State University of New York
Original Assignee
Targagenix Inc
Northeastern University Boston
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targagenix Inc, Northeastern University Boston, Research Foundation of the State University of New York filed Critical Targagenix Inc
Publication of CA3026412A1 publication Critical patent/CA3026412A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
CA3026412A 2016-06-07 2017-06-07 Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells Pending CA3026412A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662346755P 2016-06-07 2016-06-07
US62/346,755 2016-06-07
PCT/US2017/036330 WO2017214260A1 (en) 2016-06-07 2017-06-07 Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells

Publications (1)

Publication Number Publication Date
CA3026412A1 true CA3026412A1 (en) 2017-12-14

Family

ID=60578981

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3026412A Pending CA3026412A1 (en) 2016-06-07 2017-06-07 Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells

Country Status (9)

Country Link
US (3) US10206875B2 (https=)
EP (1) EP3463299A4 (https=)
JP (1) JP7518604B2 (https=)
CN (2) CN109562065A (https=)
AU (1) AU2017277497B2 (https=)
CA (1) CA3026412A1 (https=)
IL (1) IL263504A (https=)
MX (1) MX2018015112A (https=)
WO (1) WO2017214260A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017214260A1 (en) * 2016-06-07 2017-12-14 Targagenix, Inc. Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells
CN112996501A (zh) * 2017-12-20 2021-06-18 塔佳吉尼克斯公司 癌症中紫杉类纳米乳剂与免疫疗法的联合
JP7610208B2 (ja) * 2019-03-22 2025-01-08 インテグレイテッド ナノセラピューティクス インコーポレイテッド 足場部分から調製した脂質結合体
EP4048310A4 (en) * 2019-10-25 2024-03-13 Amgen Inc. COMPOSITIONS AND METHODS FOR MINIMIZING PROTEIN LOSS AT LOW PROTEIN CONCENTRATIONS
EP4054550A4 (en) * 2019-11-05 2024-01-17 Luminus Biosciences Inc. NANOPARTICLES WITH PRODRUGS STABILIZED BY ALBUMIN FOR THE TREATMENT OF CANCER AND OTHER DISEASES
CN111004195B (zh) * 2019-12-03 2022-01-28 沈阳药科大学 卡巴他赛弱碱性衍生物及其制剂
CN114317398B (zh) * 2020-09-27 2024-03-01 中国科学院分子细胞科学卓越创新中心 Gli1和EpCAM基因共同标记的肝祖细胞群及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426367B1 (en) * 1999-09-09 2002-07-30 Efa Sciences Llc Methods for selectively occluding blood supplies to neoplasias
CN1901901B (zh) * 2003-10-30 2012-07-04 纽约州州立大学研究基金会 紫杉醇-脂肪酸结合物及其药物组合物
US8557861B2 (en) * 2004-09-28 2013-10-15 Mast Therapeutics, Inc. Low oil emulsion compositions for delivering taxoids and other insoluble drugs
US20070148194A1 (en) * 2005-11-29 2007-06-28 Amiji Mansoor M Novel nanoemulsion formulations
JP5635504B2 (ja) * 2008-07-23 2014-12-03 ブハラット セルムズ アンド ヴァクシンズ リミテッド 安定した注射可能な水中油型ドセタキセルナノエマルション
US20100021471A1 (en) * 2008-07-25 2010-01-28 Brookhaven Science Associates, Llc Carbon nanotube-based drug delivery systems and methods of making same
US20140105829A1 (en) * 2012-10-15 2014-04-17 Nemucore Medical Innovations, Inc. Therapeutic nanoemulsion formulation for the targeted delivery of docetaxel and methods of making and using the same
SG11201609352TA (en) * 2014-06-19 2017-01-27 Solural Pharma ApS Solid oral dosage form of lipophilic compounds
WO2015198350A1 (en) * 2014-06-25 2015-12-30 Synergia Bio Sciences Private Limited A pharmaceutical oil-in-water nano-emulsion
WO2017214260A1 (en) * 2016-06-07 2017-12-14 Targagenix, Inc. Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells
CN112996501A (zh) * 2017-12-20 2021-06-18 塔佳吉尼克斯公司 癌症中紫杉类纳米乳剂与免疫疗法的联合

Also Published As

Publication number Publication date
US10206875B2 (en) 2019-02-19
USRE50096E1 (en) 2024-08-27
MX2018015112A (es) 2019-09-09
NZ748915A (en) 2024-09-27
CN109562065A (zh) 2019-04-02
AU2017277497B2 (en) 2023-05-04
JP2019523226A (ja) 2019-08-22
JP7518604B2 (ja) 2024-07-18
US20180028442A1 (en) 2018-02-01
EP3463299A1 (en) 2019-04-10
IL263504A (en) 2019-01-31
AU2017277497A1 (en) 2018-12-20
WO2017214260A1 (en) 2017-12-14
EP3463299A4 (en) 2020-01-15
US20250009658A1 (en) 2025-01-09
CN116019768A (zh) 2023-04-28

Similar Documents

Publication Publication Date Title
US20250009658A1 (en) Nanoemulsion compositions of taxoid drugs, and methods for the use thereof to target cancer cells and cancer stem cells
Ahmad et al. Nanoemulsion formulation of a novel taxoid DHA-SBT-1214 inhibits prostate cancer stem cell-induced tumor growth
Ravar et al. Hyaluronic acid-coated liposomes for targeted delivery of paclitaxel, in-vitro characterization and in-vivo evaluation
Zhang et al. Localized delivery of curcumin into brain with polysorbate 80-modified cerasomes by ultrasound-targeted microbubble destruction for improved Parkinson's disease therapy
Shen et al. Coating solid lipid nanoparticles with hyaluronic acid enhances antitumor activity against melanoma stem-like cells
Feng et al. Synergistic co-delivery of doxorubicin and paclitaxel by porous PLGA microspheres for pulmonary inhalation treatment
Guo et al. Size changeable nanocarriers with nuclear targeting for effectively overcoming multidrug resistance in cancer therapy
US9545382B2 (en) Nanoparticle formulations for delivering multiple therapeutic agents
Wang et al. 3-Carboxyphenylboronic acid-modified carboxymethyl chitosan nanoparticles for improved tumor targeting and inhibitory
Xu et al. Enhancing the efficacy and safety of doxorubicin against hepatocellular carcinoma through a modular assembly approach: the combination of polymeric prodrug design, nanoparticle encapsulation, and cancer cell-specific drug targeting
Qu et al. Oral nanomedicine based on multicomponent microemulsions for drug-resistant breast cancer treatment
Sabzichi et al. Fabrication of all-trans-retinoic acid-loaded biocompatible precirol: A strategy for escaping dose-dependent side effects of doxorubicin
Guo et al. Transferrin-functionalized microemulsions coloaded with coix seed oil and tripterine deeply penetrate to improve cervical cancer therapy
US12186428B2 (en) Combination taxoid nanoemulsion with immunotherapy in cancer
Vaez et al. A bright horizon of intelligent targeted-cancer therapy: nanoparticles against breast cancer stem cells
Rajendra et al. Fabrication and in vitro evaluation of silk fibroin-folic acid decorated paclitaxel and hydroxyurea nanostructured lipid carriers for targeting ovarian cancer cells: A double sword approach
Myat et al. Antibody-decorated chitosan-iodoacetamide-coated nanocarriers for the potential delivery of doxorubicin to breast cancer cells
Wen et al. Functional exosomes modified with chitosan effectively alleviate anthracycline-induced cardiotoxicity
Kong et al. Targeted codelivery of doxorubicin and oleanolic acid by reduction responsive hyaluronic acid-based prodrug nano-micelles for enhanced antitumor activity and reduced toxicity
KR101314579B1 (ko) 파크리탁셀이 선적된 고분자 나노입자 및 그 제조방법
Alavi et al. Synthesis and Evaluation of the Anticancer Effects of Iron Oxide-Chitosan Magnetic Nanoparticles Loaded Atorvastatin on the Invasion and Tumorigenicity of C6 Cell Line in Glioblastoma Animal Model
Huang et al. Antitumor efficacy of docetaxel-loaded nanocarrier against esophageal cancer cell bearing mice model
Alvarado-Palacios et al. Nanoencapsulation of the Aranto (Kalanchoe daigremontiana) aquoethanolic extract by nanospray dryer and its selective effect on breast cancer cell line
Gad Targeted therapy for aggressive lung cancer
Movahedi et al. PD-L1-Targeted Co-Delivery of Two Chemotherapeutics for Efficient Suppression of Skin Cancer Growth. Pharmaceutics 2022, 14, 1488

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220527

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240702

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20240830

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241217

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250109

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: N-6-6-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250109

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250313

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250313

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250313

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260416

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260416